PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsNelfinavir
Viracept(nelfinavir)
Viracept (nelfinavir) is a small molecule pharmaceutical. Nelfinavir was first approved as Viracept on 1997-03-14. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Viracept (discontinued: Viracept)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nelfinavir mesylate
Tradename
Company
Number
Date
Products
VIRACEPTAgouron PharmaceuticalsN-020779 RX1997-03-14
1 products, RLD, RS
VIRACEPTAgouron PharmaceuticalsN-021503 RX2003-04-30
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
viraceptNew Drug Application2024-03-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE04: Nelfinavir
HCPCS
No data
Clinical
Clinical Trials
148 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20173322730105
LipodystrophyD008060—E88.11——3—4
Healthy volunteers/patients———1——2—3
TuberculosisD014376EFO_0000774A15-A191——113
Cardiovascular diseasesD002318EFO_0000319I98———1—1
Hiv-associated lipodystrophy syndromeD039682EFO_1001348————1—1
Hepatitis cD006526—B19.2———1—1
HepatitisD006505—K75.9———1—1
Hepatitis aD006506EFO_0007305B15———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acquired immunodeficiency syndromeD000163EFO_0000765B20—65—515
InfectionsD007239EFO_0000544——72—514
Communicable diseasesD003141———11—57
PregnancyD011247EFO_0002950Z33.11—1—13
Uterine cervical neoplasmsD002583——2—1——3
CarcinomaD002277—C80.0—11——2
Kidney diseasesD007674EFO_0003086N08——1——1
Aids-associated nephropathyD016263EFO_0007313———1——1
DiarrheaD003967—R19.7——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8061———6
SarcomaD012509——24———5
Non-small-cell lung carcinomaD002289——14———4
Multiple myelomaD009101—C90.032———4
Pancreatic neoplasmsD010190EFO_0003860C2532———4
Kaposi sarcomaD012514—C4613———4
Plasma cell neoplasmsD054219——22———3
Lung neoplasmsD008175—C34.9023———3
HivD006678—O98.7—1——12
Renal cell carcinomaD002292EFO_0000376—11———2
Show 19 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.93————3
GlioblastomaD005909EFO_0000515—3————3
LeukemiaD007938—C951————1
PlasmacytomaD010954—C90.31————1
Hiv seronegativityD018023——1————1
GliomaD005910EFO_0000520—1————1
Central nervous system neoplasmsD016543——1————1
Nervous system neoplasmsD009423——1————1
Cardiopulmonary bypassD002315——1————1
LymphopeniaD008231—D72.8101————1
Show 11 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Disease progressionD018450——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNelfinavir
INNnelfinavir
Description
Nelfinavir is an aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. It has a role as a HIV protease inhibitor and an antineoplastic agent. It is a member of benzamides, a member of phenols, an aryl sulfide, a secondary alcohol, a tertiary amino compound and an organic heterobicyclic compound. It is a conjugate base of a nelfinavir(1+).
Classification
Small molecule
Drug classantivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
Identifiers
PDB—
CAS-ID159989-64-7
RxCUI—
ChEMBL IDCHEMBL584
ChEBI ID7496
PubChem CID64143
DrugBankDB00220
UNII IDHO3OGH5D7I (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nelfinavir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,210 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,829 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use